Limited Submission: Pilot Projects in Non-AIDS Defining Cancers
DEADLINE: February 27, 2017
With support from a supplement to its NCI P30 grant, the Case Comprehensive Cancer Center in coordination with the CWRU/UH Center for AIDS Research (CFAR) is providing seed funding for the development of cancer research projects focusing on the interface between aging and HIV infection in Non-AIDS Defining Cancers (NADC). The goal of this RFA is to build collaborative projects in cancer biology, aging, immunology, HIV/AIDS, systems biology/informatics, geriatric oncology, geriatric epidemiology, and/or cancer survivorship that will be competitive for nationally-funded multi-PI awards.
An information session will be held in September (date pending) to discuss the goals of the pilot program, facilitate building of NADC teams, describe funding criteria, and outline plans for future grant applications. All teams planning to submit a project should attend.
- Funding for research teams with a focus on unique aspects of aging and NADC in HIV positive patients
- FOUR research projects will be awarded over two rounds of funding
- Each research project will be funded at a level up to $50,000 for one year
- Applications must focus on NADC in HIV-positive patients
- Interactions with HIV research teams and/or patient cohorts from the CWRU/UH CFAR and/or Uganda is strongly encouraged.
- Use of the national CFAR Network of Integrated Clinical Systems (CNICS) database and CWRU/UH CFAR database is encouraged. The CWRU/UH CFAR database is under development and will be ready to use for the February 2017 deadline.
- Strong collaborative investigative teams led by independent faculty at any one or more of the Case CCC institutions
- Highly innovative and impactful projects
- Projects must have a high likelihood of subsequent national-level funding of multi-PI grants
- Strong biostatistical or bioinformatic support
- Limit of ONE application per lead PI. Investigators can be collaborators on multiple applications
- All applications will be reviewed in two stages that include 1) evaluation of the research proposed in the written proposal and 2) an oral presentation by the PI/Co-PIs to the review panel with questions/discussion.
- Applications must follow the specific instructions for this RFA.
- Case CCC Pilot Application Cover Page [View pdf: Case CCC-pilot-app-cover-template]
- Case CCC Pilot Application Budget Form [View pdf: CaseCCC-pilot-app-budget-form-singleyr]
- Instructions [View pdf: NADC-defining-cancers-2016-instructions]
Contact Megan Kilbane, Assistant Dean for Oncology, firstname.lastname@example.org
Request for Applications: Opportunities for Pilot Projects from VeloSano Bike to Cure
DEADLINE: March 6, 2017
With the generous support from VeloSano Bike to Cure 2016, the Case Comprehensive Cancer Center is providing seed funding for the initiation of novel projects aligned with at least one of the seven Research Programs (GI Cancer Genetics, Molecular Oncology, GU Malignancies, Hematopoietic and Immune Cancer Biology, Developmental Therapeutics, Cancer Imaging, or Cancer Prevention, Control, & Population Research) or the Brain Tumor or Breast Cancer research initiatives within the Center. Highly innovative and impactful proposals are sought that will generate key data for larger, nationally competitive grants that interface with the Strategic Plan of the aligned program(s). Proposals must include collaborative, multi-investigator projects. In addition, projects that focus on renal cancer biology, disparities research, brain tumors, or drug discovery and screening are particularly encouraged.
Eligibility for funds will be restricted to lead PIs that are Center members who participated in VeloSano Bike to Cure 2016 (rider, virtual rider, or volunteer). In addition, the lead PI of the application must not be eligible for CCF VeloSano funding. Co-PIs and Co-investigators are not required to have been VeloSano participants. All awardees (PIs and co-investigators) will be expected to participate in VeloSano 2017 as well as to present their research progress when requested by the Case Comprehensive Cancer Center.
- Funding for research teams with projects that are aligned with one of the Cancer Center Research Programs.
- Up to 7 research projects will be funded. Total funds committed to this RFA are $350,000.
- Each research project can request a budget of up to $50,000 over two years.
- Research projects should be completed within two years.
- Strong collaborative investigative teams of Case Comprehensive Cancer Center members that clearly demonstrate programmatic alignment.
- Highly innovative and impactful projects.
- All materials to complete the project should be in-hand or readily available. For example, tissue-based research will require an approved IRB protocol and patient cohort studies must have already recruited the cohort. Collection of new patient cohorts is not responsive to this RFA.
- Projects must have a high likelihood of subsequent national-level funding.
- While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI.
- All funds for core facilities must use Case Comprehensive Cancer Center cores, when available, rather than cores at institutions outside Cleveland.
- A letter from the Program Leader of the PI indicating alignment of the project with the program must be included.
View detailed instructions: [VeloSano-Instructions-2017]
Contact email@example.com or Megan Kilbane at 216.286.4440 with any questions.
Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.
The proposals are being accepted on a rolling basis subject to availability of funds.
Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office, firstname.lastname@example.org, 216.844.4176.